ArticleRetina (Philadelphia, Pa.)2018
LONGITUDINAL CORRELATION OF ELLIPSOID ZONE LOSS AND FUNCTIONAL LOSS IN MACULAR TELANGIECTASIA TYPE 2.
Article in Retina (Philadelphia, Pa.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed.
- Functional Relevance of Hyper-Reflectivity in Macular Telangiectasia Type 2.Investigative ophthalmology & visual science · 2021Trial
- Retinal cavitations in macular telangiectasia type 2 (MacTel): longitudinal structure-function correlations.The British journal of ophthalmology · 2021Trial
- Correlation Between Macular Integrity Assessment and Optical Coherence Tomography Imaging of Ellipsoid Zone in Macular Telangiectasia Type 2.Investigative ophthalmology & visual science · 2017Trial
- Macular Holes Secondary to Macular Telangiectasia Type 2: Pathogenesis, Clinical Features, Imaging and Surgical Management.Journal of clinical medicine · 2026Review
- Topographically Resolved Macular Pigment Optical Density Is Associated with Disease Progression in Macular Telangiectasia Type 2.Ophthalmology science · 2026Article
- Macular telangiectasia type 2: An update.The Journal of international medical research · 2026Review
- Automated OCT-tailored and same-visit biomarker-targeted microperimetry in geographic atrophy.Scientific reports · 2026Article
- Macular Telangiectasia Type 2: The Role of Optical Coherence Tomography and Management Options.Journal of clinical medicine · 2026Review
- Validation of Macular Telangiectasia Type-2 (MacTel) multimodal imaging-based classification system in a cohort from India.Eye (London, England) · 2026Article
- Prognostic Relevance of Relative Ellipsoid Zone Reflectivity for Ellipsoid Zone Loss in Macular Telangiectasia Type 2.Investigative ophthalmology & visual science · 2024Observational
- Skeleton density and ellipsoid zone loss are prognostic for progression in Macular Telangiectasia Type 2.Scientific reports · 2024Article
- OCT Biomarkers in Ocular CLN2 Disease in Patients Treated With Intraventricular Enzyme Replacement Therapy.Investigative ophthalmology & visual science · 2024Article
- Evaluation and comparison of microperimetry and optical coherence tomography findings in patients with Behçet uveitis.International ophthalmology · 2024Article
- Unraveling the mysteries of macular telangiectasia 2: the intersection of philanthropy, multimodal imaging and molecular genetics. The 2022 founders lecture of the pan American vitreoretinal society.International journal of retina and vitreous · 2023Review
- Optical coherence tomography: when a picture is worth a million words.The Journal of clinical investigation · 2023Article
- Relative Ellipsoid Zone Reflectivity in Macular Telangiectasia Type 2.Investigative ophthalmology & visual science · 2023Article
- iPSC-derived retinal pigmented epithelial cells from patients with macular telangiectasia show decreased mitochondrial function.The Journal of clinical investigation · 2023Article
- One-year follow-up of optical coherence tomography angiography microvascular findings: macular telangiectasia type 2 versus tamoxifen retinopathy.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2022Article
- Structural-vascular-functional correlation in type 2 non-proliferative macular telangiectasia.International journal of retina and vitreous · 2022Article
- Visual acuity after cataract surgery in Macular Telangiectasia Type 2 Stage 3 to 5.International journal of retina and vitreous · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
purposeTo compare ellipsoid zone (EZ) loss and functional loss in macular telangiectasia (MacTel) type 2 longitudinally.
methodsProspective natural history study. Ellipsoid zone loss was measured in en-face images created from spectral domain optical coherence tomography. Functional loss was assessed by best-corrected visual acuity and microperimetry, counting the number of test points with impaired function.
resultsA total of 56 eyes of 31 participants were followed for 4.5 ± 1.2 years. Ellipsoid zone loss was 18,600 ± 3,917.3 pixel at baseline (≈0.59 mm) and increased 2,627.8 ± 427.9 pixel (≈0.08 mm) per year. Best-corrected visual acuity decreased 2.2 ± 0.9 letters per year. Change in EZ loss correlated significantly with change in relative and absolute scotomas (r = 0.62; P-value < 0.0001 and r = 0.72; P-value < 0.0001), but not with loss of best-corrected visual acuity. Functional loss showed a similar frequency of progression as EZ loss, but a higher rate of "regression," likely due to higher variability of the measurement, assuming a progressive neurodegenerative disease.
conclusionThe results of the authors support EZ loss as surrogate measure for visual function in MacTel type 2. Being objective, EZ loss might be considered more suitable than microperimetry as primary end point in future interventional trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.